Developer docs
API playgroundTry for free, no card

Search company profiles

FluoGuide

Full company profile

uuid0000c3c

Namestring
FluoGuide
Legal namestring
FluoGuide A/S
Websiteurl
fluoguide.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

FluoGuide A/S is a Danish clinical-stage biotechnology company developing FG001, a fluorescent intraoperative imaging agent designed to label cancer cells in real time during surgery, enabling surgeons to visually distinguish tumor tissue from healthy tissue. The company is headquartered in Copenhagen, Denmark, and has been publicly listed on Nasdaq First North Sweden under the ticker FLUO since at least November 2025. FG001 targets aggressive brain cancer (high-grade glioma) as its lead indication, with additional development in head and neck cancer, meningioma, and low-grade glioma. In February 2026 the FDA cleared the IND application for FG001 in high-grade glioma, and in March 2026 the FDA granted Fast Track Designation, positioning the asset for a U.S. Phase 2 registration trial with first patient enrollment planned for Q2 2026.

The company's technology is a small-molecule fluorescent probe that binds to cancer cells and emits a signal when illuminated intraoperatively, integrating with leading surgical microscopy platforms via non-exclusive collaborations with ZEISS Medical Technologies (signed November 2025) and Olympus. FluoGuide is pre-revenue: it reported no commercial revenue for FY2025 and a consolidated net loss of tDKK 39,459. Operations are funded primarily by equity capital, most recently a SEK 104 million directed share issue completed in November 2025 via accelerated bookbuilding to Nordic institutional investors. Headcount is small (1–10 employees as listed), with leadership consisting of CEO Morten Albrechtsen, CFO Ole Larsen, and COO Donna Haire (appointed November 2025).

Commercially, FluoGuide expects to generate revenue upon regulatory approval and launch of FG001, with go-to-market built around enterprise sales to hospitals and surgical centers, leveraging its microscopy-platform integrations. Two U.S. registration-enabling clinical trials are anticipated for the high-grade glioma program. The business model is effectively a single-asset, regulatory-driven biotech dependent on successful clinical readouts, FDA approval, and downstream commercialization or partnership economics.

Short descriptiontext

FluoGuide A/S is a Copenhagen-based clinical-stage biotech developing FG001, a fluorescent imaging agent that lights up cancer cells during surgery to guide tumor resection in high-grade glioma, head and neck, and other cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intraoperative imaging agent, surgical oncology pharmaceuticals, fluorescence-guided surgery, cancer surgery visualization, biopharmaceutical drug development
Industry3 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Intraoperative Surgical Oncology Imaging
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biotech Product Revenue
TypeOne Time License
Description

Pre-revenue company developing FG001 as an intraoperative imaging agent. The company expects to generate revenue upon regulatory approval and commercialization of its surgical imaging technology for cancer treatment.

pharmiweb.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FluoGuide develops and commercializes FG001, a proprietary surgical imaging agent designed to improve precision in cancer surgery by fluorescently labeling cancer cells so they light up intraoperatively. The product enables real-time visual identification of tumor margins during resection procedures and is being advanced for high-grade glioma, head and neck cancer, meningioma, and low-grade glioma indications through clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Positive interim results from FG001 trial in meningioma and low-grade glioma
Product overview1 text field

FluoGuide is a pharmaceutical/biotechnology company with a single lead product, FG001, which is a surgical imaging agent designed for intraoperative tumor visualization. The company is developing FG001 for multiple cancer indications including high-grade glioma, head and neck cancer, meningioma, and low-grade glioma. FG001 works by fluorescently labeling cancer cells to enable real-time visual identification during surgery, with strategic collaborations with ZEISS and Olympus for surgical microscopy integration.

Product and service1 record
1FG001
CategoryIntraoperative Surgical Oncology Imaging Agent
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-25
Description

Collaboration agreement with ZEISS Medical Technologies to develop FG001 for tumor imaging and surgical margins assessment in head and neck cancer. The collaboration focuses on supporting the clinical phase with no initial payment. This is a non-exclusive agreement and is not expected to impact the company's financial results in 2025.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic collaboration with Olympus for development and integration of FG001 surgical imaging technology. Olympus is a leading medical technology company focused on head and neck cancer surgery solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Blaze Bioscience develops 'Tumor Paint' (tozuleristide/BLZ-100), a fluorescent imaging agent that labels cancer cells intraoperatively — directly comparable to FluoGuide's FG001 in mechanism, use case (real-time intraoperative tumor illumination), and target surgical indications including brain tumors.

TypeDirect peer
Description

Lumicell develops the LUM System, a fluorescence-guided imaging platform combined with a tumor-targeted imaging agent (pegulicianine) for intraoperative cancer detection during breast cancer surgery — same combination-product architecture and intraoperative use case as FG001.

3Avelas Biosciences
TypeDirect peer
Description

Avelas develops fluorescent imaging agents (e.g., AVB-620 / pegloprastide) for real-time intraoperative visualization of cancer tissue, directly comparable to FluoGuide's FG001 in product category and surgical oncology application.

TypeBroad incumbent
Description

Stryker owns the Novadaq/SPY portfolio of fluorescence imaging platforms used in surgical visualization across multiple specialties — broadly overlaps with FG001's fluorescence-guided surgery application as part of a much wider surgical equipment portfolio.

TypeBroad incumbent
Description

Intuitive's da Vinci surgical systems include Firefly fluorescence imaging for intraoperative visualization, addressing the same surgical oncology workflows FluoGuide targets with FG001, though as part of a much broader robotic surgery platform.

TypeBroad incumbent
Description

Medtronic offers near-infrared fluorescence imaging integrated into its surgical platforms (e.g., neurosurgery visualization) — broadly competing with FG001's intraoperative tumor illumination value proposition as part of a diversified medtech portfolio.

TypeBroad incumbent
Description

Karl Storz provides endoscopic visualization platforms with integrated ICG-based fluorescence imaging for surgical oncology — broadly overlapping with FluoGuide's surgical microscopy / endoscopy integration use case.

TypeBroad incumbent
Description

Olympus is both a strategic collaboration partner for FG001 and a major surgical visualization competitor with its own endoscopy and microscopy platforms used in head and neck cancer surgery — a dual partner/incumbent relationship in the same surgical imaging space.

TypeBroad incumbent
Description

Leica Microsystems, part of Danaher, supplies surgical microscopy platforms used in neurosurgery and ENT — directly relevant as a potential integration partner / competitor to FluoGuide's ZEISS and Olympus collaborations for fluorescence-guided intraoperative imaging.

TypeEmerging player
Description

Perimeter Medical Imaging AI develops imaging AI plus wide-field OCT for intraoperative margin assessment during breast-conserving surgery — an emerging alternative modality to fluorescence-guided imaging that overlaps with FluoGuide's surgical oncology use case.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FluoGuide

Intraoperative Surgical Oncology Imagingfluoguide.com

FluoGuide A/S is a Copenhagen-based clinical-stage biotech developing FG001, a fluorescent imaging agent that lights up cancer cells during surgery to guide tumor resection in high-grade glioma, head and neck, and other cancers.

What FluoGuide does

FluoGuide A/S is a Danish clinical-stage biotechnology company developing FG001, a fluorescent intraoperative imaging agent designed to label cancer cells in real time during surgery, enabling surgeons to visually distinguish tumor tissue from healthy tissue. The company is headquartered in Copenhagen, Denmark, and has been publicly listed on Nasdaq First North Sweden under the ticker FLUO since at least November 2025. FG001 targets aggressive brain cancer (high-grade glioma) as its lead indication, with additional development in head and neck cancer, meningioma, and low-grade glioma. In February 2026 the FDA cleared the IND application for FG001 in high-grade glioma, and in March 2026 the FDA granted Fast Track Designation, positioning the asset for a U.S. Phase 2 registration trial with first patient enrollment planned for Q2 2026.

The company's technology is a small-molecule fluorescent probe that binds to cancer cells and emits a signal when illuminated intraoperatively, integrating with leading surgical microscopy platforms via non-exclusive collaborations with ZEISS Medical Technologies (signed November 2025) and Olympus. FluoGuide is pre-revenue: it reported no commercial revenue for FY2025 and a consolidated net loss of tDKK 39,459. Operations are funded primarily by equity capital, most recently a SEK 104 million directed share issue completed in November 2025 via accelerated bookbuilding to Nordic institutional investors. Headcount is small (1–10 employees as listed), with leadership consisting of CEO Morten Albrechtsen, CFO Ole Larsen, and COO Donna Haire (appointed November 2025).

Commercially, FluoGuide expects to generate revenue upon regulatory approval and launch of FG001, with go-to-market built around enterprise sales to hospitals and surgical centers, leveraging its microscopy-platform integrations. Two U.S. registration-enabling clinical trials are anticipated for the high-grade glioma program. The business model is effectively a single-asset, regulatory-driven biotech dependent on successful clinical readouts, FDA approval, and downstream commercialization or partnership economics.

FluoGuide firmographics

Firmographics
Name
FluoGuide
Legal name
FluoGuide A/S
Website
https://fluoguide.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
FluoGuide A/S is a Copenhagen-based clinical-stage biotech developing FG001, a fluorescent imaging agent that lights up cancer cells during surgery to guide tumor resection in high-grade glioma, head and neck, and other cancers.
Ownership category
akta.pro rank

FluoGuide industry classification

Industry
Product category
Intraoperative Surgical Oncology Imaging
NAICS
Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Intraoperative imaging agent
  • Surgical oncology pharmaceuticals
  • Fluorescence-guided surgery
  • Cancer surgery visualization
  • Biopharmaceutical drug development

Where FluoGuide is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

FluoGuide business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical/Biotech Product Revenue: Pre-revenue company developing FG001 as an intraoperative imaging agent. The company expects to generate revenue upon regulatory approval and commercialization of its surgical imaging technology for cancer treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

FluoGuide product offering

Product offering

Core offering

FluoGuide develops and commercializes FG001, a proprietary surgical imaging agent designed to improve precision in cancer surgery by fluorescently labeling cancer cells so they light up intraoperatively. The product enables real-time visual identification of tumor margins during resection procedures and is being advanced for high-grade glioma, head and neck cancer, meningioma, and low-grade glioma indications through clinical trials.

Product overview

FluoGuide is a pharmaceutical/biotechnology company with a single lead product, FG001, which is a surgical imaging agent designed for intraoperative tumor visualization. The company is developing FG001 for multiple cancer indications including high-grade glioma, head and neck cancer, meningioma, and low-grade glioma. FG001 works by fluorescently labeling cancer cells to enable real-time visual identification during surgery, with strategic collaborations with ZEISS and Olympus for surgical microscopy integration.

Differentiator

Problem solved

Functional benefit

Products and services

  • FG001

Quantifiable outcome

  • Positive interim results from FG001 trial in meningioma and low-grade glioma

Companies that use FluoGuide

Customer profile

Segments3 records

Ideal customer profiles1 record

FluoGuide technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature1 record

FluoGuide partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ZEISS Medical TechnologiescoreTechnology or Integration · 25 November 2025Collaboration agreement with ZEISS Medical Technologies to develop FG001 for tumor imaging and surgical margins assessment in head and neck cancer. The collaboration focuses on supporting the clinical phase with no initial payment. This is a non-exclusive agreement and is not expected to impact the company's financial results in 2025.
  • OlympuscoreTechnology or IntegrationStrategic collaboration with Olympus for development and integration of FG001 surgical imaging technology. Olympus is a leading medical technology company focused on head and neck cancer surgery solutions.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

FluoGuide competitors and assessment

Company assessment

Direct peers

  • Blaze Bioscience: Blaze Bioscience develops 'Tumor Paint' (tozuleristide/BLZ-100), a fluorescent imaging agent that labels cancer cells intraoperatively — directly comparable to FluoGuide's FG001 in mechanism, use case (real-time intraoperative tumor illumination), and target surgical indications including brain tumors.
  • Lumicell: Lumicell develops the LUM System, a fluorescence-guided imaging platform combined with a tumor-targeted imaging agent (pegulicianine) for intraoperative cancer detection during breast cancer surgery — same combination-product architecture and intraoperative use case as FG001.
  • Avelas Biosciences: Avelas develops fluorescent imaging agents (e.g., AVB-620 / pegloprastide) for real-time intraoperative visualization of cancer tissue, directly comparable to FluoGuide's FG001 in product category and surgical oncology application.

Broad incumbents

  • Stryker: Stryker owns the Novadaq/SPY portfolio of fluorescence imaging platforms used in surgical visualization across multiple specialties — broadly overlaps with FG001's fluorescence-guided surgery application as part of a much wider surgical equipment portfolio.
  • Intuitive Surgical: Intuitive's da Vinci surgical systems include Firefly fluorescence imaging for intraoperative visualization, addressing the same surgical oncology workflows FluoGuide targets with FG001, though as part of a much broader robotic surgery platform.
  • Medtronic: Medtronic offers near-infrared fluorescence imaging integrated into its surgical platforms (e.g., neurosurgery visualization) — broadly competing with FG001's intraoperative tumor illumination value proposition as part of a diversified medtech portfolio.
  • Karl Storz: Karl Storz provides endoscopic visualization platforms with integrated ICG-based fluorescence imaging for surgical oncology — broadly overlapping with FluoGuide's surgical microscopy / endoscopy integration use case.
  • Olympus: Olympus is both a strategic collaboration partner for FG001 and a major surgical visualization competitor with its own endoscopy and microscopy platforms used in head and neck cancer surgery — a dual partner/incumbent relationship in the same surgical imaging space.
  • Leica Microsystems (Danaher): Leica Microsystems, part of Danaher, supplies surgical microscopy platforms used in neurosurgery and ENT — directly relevant as a potential integration partner / competitor to FluoGuide's ZEISS and Olympus collaborations for fluorescence-guided intraoperative imaging.

Emerging players

  • Perimeter Medical Imaging AI: Perimeter Medical Imaging AI develops imaging AI plus wide-field OCT for intraoperative margin assessment during breast-conserving surgery — an emerging alternative modality to fluorescence-guided imaging that overlaps with FluoGuide's surgical oncology use case.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

FluoGuide social profiles

Digital presence

FluoGuide financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FluoGuide leadership team

Management profile

Number of profiles

Profiles7 records

FluoGuide funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FluoGuide M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FluoGuide

What does FluoGuide do?

FluoGuide develops and commercializes FG001, a proprietary surgical imaging agent designed to improve precision in cancer surgery by fluorescently labeling cancer cells so they light up intraoperatively. The product enables real-time visual identification of tumor margins during resection procedures and is being advanced for high-grade glioma, head and neck cancer, meningioma, and low-grade glioma indications through clinical trials.

Is FluoGuide a public or private company?

FluoGuide is a public company. It is classified as public and is currently operating.

When was FluoGuide founded?

FluoGuide was founded in 2018. It employs 11 to 50 people.

Where is FluoGuide based?

FluoGuide is headquartered in Copenhagen, Denmark, in the Europe region.

How does FluoGuide make money?

One revenue line is on record: pharmaceutical/Biotech Product Revenue.

Who are FluoGuide's main competitors?

Direct peers on record are Blaze Bioscience, Lumicell and Avelas Biosciences. Broad incumbents are Stryker, Intuitive Surgical, Medtronic, Karl Storz, Olympus and Leica Microsystems (Danaher). Perimeter Medical Imaging AI is listed as an emerging player.

Does FluoGuide have an API?

No public API is recorded for FluoGuide.

What industry is FluoGuide in?

FluoGuide's product category is Intraoperative Surgical Oncology Imaging. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewFluoGuide A/S invites investors to Q3 webcast - Clinical progress and the road aheadFluoGuide A/S will publish its Q3 2026 interim report on 26 November 2026, followed by a live investor webcast at 14:00 CET. CEO Morten Albrechtsen and CFO Ole Larsen will present operational and financial results, including an update on the US pivotal trial of FG001 in high-grade glioma, and upcoming milestones.MarketScreenerDNB Carnegie: Fluoguide's recruitment start strengthens execution outlookDNB Carnegie sees Fluoguide's recruitment start as confirmation the program is progressing despite prior delays. The bank estimates a 50% probability of approval in high-grade glioma, rising to 75% on positive data, with a fair value of SEK 20-70 per share.The future of tradingFluoGuide partners with Leica Microsystems on brain tumor surgery imagingFluoGuide entered a non-exclusive collaboration with Leica Microsystems to support development of its FG001 imaging agent for brain tumor surgery, targeting clinical-phase support in high-grade glioma. The agreement includes no upfront payment, and management expects no impact on 2026 financial results.Investing.comEarnings call transcript: FluoGuide advances U.S. cancer trial setup in H1 2026 By Investing.comFluoGuide reported first-half 2026 results, posting a net loss of DKK 24.6 million and cash burn of DKK 29 million, with DKK 50 million in cash and securities. The company received FDA approval for its first U.S. high-grade glioma site and Fast Track designation, with seven more sites near activation. Head and neck interim results were delayed to early 2027.MorningstarFluoGuide A/S Publishes Interim Report for Q2 2026FluoGuide published its Q2 2026 interim report, reporting positive results from its Phase 2 trial in oral head and neck cancer and the first U.S. site activation for FG001-CT-006. The company's net loss widened to DKK 12,819 thousand, and equity share fell to 47%.BioSpaceFluoGuide A/S Publishes Interim Report for Q2 2026FluoGuide published its Q2 2026 interim report, reporting positive results from its Phase 2 trial in oral head and neck cancer and activating the first U.S. site for a pivotal trial. The company's net loss widened to DKK 12,819, and equity share fell to 47%.YahooInvitation to FluoGuide A/S Live Webcast on 25 August 2026FluoGuide A/S announced it will publish its interim report for Q2 2026 on Tuesday, 25 August 2026. CEO Morten Albrechtsen and CFO Ole Larsen are scheduled to present the company's operational and financial results during a live webcast hosted by BioStock later that day.MorningstarUpdate on 2026 Outlook and Company ProgressFluoGuide reported positive results on all 2026 milestones with minor timing adjustments. The company submitted an IND for FG001 in brain cancer and expects first patient enrollment in July 2026. It also plans to present a brain tumor plan in H2 2026.MorningstarFluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer TrialFluoGuide announced positive results from the first part of its FG001 Phase 2 trial for oral head and neck cancer, with 15 patients completing surgery. The optimal dose was identified as 0.30 mg/kg, and the drug was well tolerated. Part 2 of the trial will evaluate additional timing windows, with enrollment planned for Q4 2026.MarketScreenerFluoguide reports planned loss: CEO signals progress toward registrational development in the USFluoguide reported a Q1 2026 loss of DKK 13.3 million, with net loss of DKK 11.8 million and EPS of DKK -0.72. CEO Morten Albrechtsen said the company advanced FG001 toward US registrational development, citing FDA IND clearance and Fast Track designation. He expects continued momentum in 2026.